title: Carboplatin-induced Fanconi-like syndrome in rats: amelioration by pentoxifylline.
abstract: BACKGROUND
  Carboplatin is a congener of cisplatin used in the treatment of ovarian, head and neck and small-cell lung cancer. However, the clinical efficacy of carboplatin is marred by the development of ROS-dependent nephrotoxicity. The pathophysiological damage inflicted upon the kidney by carboplatin closely resembles to that of Fanconi syndrome.
  
  
  OBJECTIVE
  The present study aimed at inducing Fanconi-like syndrome in rats by administration of carboplatin. Objectives of the study involved evaluation of biochemical parameters coherent to Fanconi-like syndrome. Further, an attempt was made to evaluate the potential therapeutic effect of pentoxifylline in this condition.
  
  
  RESULTS
  The results of the study demonstrated that the urinary excretion profile of carboplatin treated rats closely resembled to that of patients suffering from Fanconi-like condition. Pentoxifylline was able to ameliorate this nephrotoxic condition as suggested by the change in levels of membrane bound ATPases, MDA and GSH. The urinary levels of tyrosine and cysteine correlate well with that of Fanconi-like condition in animals and humans.
  
  
  CONCLUSIONS
  In lieu of these observations, our study suggested that carboplatin-induced renovascular damage resembles to Fanconi-like condition which can be mitigated by pentoxifylline.
authors.affiliation: Pharmacology Laboratory, Pharmacy Department, Faculty of Technology and Engineering, The M.S. University of Baroda, India.
authors.forename: Ravi
authors.initials: R
authors.lastname: Khakhariya
authors.affiliation: Pharmacology Laboratory, Pharmacy Department, Faculty of Technology and Engineering, The M.S. University of Baroda, India.
authors.forename: S P
authors.initials: SP
authors.lastname: Rathod
authors.affiliation: Pharmacology Laboratory, Pharmacy Department, Faculty of Technology and Engineering, The M.S. University of Baroda, India. Electronic address: gandhihardikp@gmail.com.
authors.forename: Hardik
authors.initials: H
authors.lastname: Gandhi
authors.affiliation: Pharmacology Laboratory, Pharmacy Department, Faculty of Technology and Engineering, The M.S. University of Baroda, India.
authors.forename: Bhavesh
authors.initials: B
authors.lastname: Variya
authors.affiliation: Pharmacology Laboratory, Pharmacy Department, Faculty of Technology and Engineering, The M.S. University of Baroda, India.
authors.forename: Jinal
authors.initials: J
authors.lastname: Trivedi
authors.affiliation: Pharmaceutical Quality Assurance Laboratory, Pharmacy Department, Faculty of Technology and Engineering, The M.S. University of Baroda, India.
authors.forename: Prachi
authors.initials: P
authors.lastname: Bhamre
authors.affiliation: Pharmaceutical Quality Assurance Laboratory, Pharmacy Department, Faculty of Technology and Engineering, The M.S. University of Baroda, India.
authors.forename: S J
authors.initials: SJ
authors.lastname: Rajput
mesh_terms: D000251:Adenosine Triphosphatases / Q000378:metabolism; D000818:Animals; D000970:Antineoplastic Agents / Q000633:toxicity*; D001806:Blood Urea Nitrogen; D016190:Carboplatin / Q000633:toxicity*; D003404:Creatinine / Q000097:blood; D003545:Cysteine / Q000652:urine; D005260:Female; D005978:Glutathione / Q000378:metabolism; D006968:Hypersensitivity, Delayed / Q000139:chemically induced* / Q000188:drug therapy / Q000378:metabolism; D007153:Immunologic Deficiency Syndromes / Q000139:chemically induced* / Q000188:drug therapy / Q000378:metabolism; D007668:Kidney / Q000187:drug effects / Q000378:metabolism; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D010198:Pancytopenia / Q000139:chemically induced* / Q000188:drug therapy / Q000378:metabolism; D010431:Pentoxifylline / Q000494:pharmacology* / Q000627:therapeutic use; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D012878:Skin Neoplasms / Q000139:chemically induced* / Q000188:drug therapy / Q000378:metabolism; D014443:Tyrosine / Q000652:urine; D014527:Uric Acid / Q000097:blood
chemical_list: D000970:Antineoplastic Agents; D010726:Phosphodiesterase Inhibitors; D014527:Uric Acid; D014443:Tyrosine; D008315:Malondialdehyde; D003404:Creatinine; D016190:Carboplatin; D000251:Adenosine Triphosphatases; D005978:Glutathione; D003545:Cysteine; D010431:Pentoxifylline
keywords: Carboplatin; Cysteinuria; Fanconi syndrome; Pentoxifylline; Tyrosinuria